Glenmark Pharmaceuticals Initiates Recall of 1.5 Million Bottles of ADHD Medication in the US
Overview of the Recall Glenmark Pharmaceuticals, a prominent global pharmaceutical company, has initiated a voluntary recall of approximately 1.5 million bottles of Atomoxetine Capsules in the United States. Atomoxetine is a medication commonly prescribed for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). This recall encompasses multiple strengths of the medication and is primarily due … Read more